VBI Vaccines Logo
CA91822J1030
A2AJ0L
VBIV

VBI Vaccines

Forecast

Buy
  6
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2006, VBI Vaccines has already paid €0.62 in dividends. The last payout was in January 2006.

Financials

In the last year, VBI Vaccines had revenue of €7.85m and net profit of -€83.98m

(EUR) 2023
YoY
Revenue 7.85m 678.61%
Gross profit -5.26m 44.65%
Net profit -83.98m 36.09%
EBITDA -74.88m 24.23%

Fundamentals

Metric Value
Market capitalization
€1.71m
Number of shares
28.68m
52-week high/low
€1.23 - €0.0523
Dividends No
Beta
2.17
P/E ratio
-0.01
PEG ratio
0.00
P/B ratio
0.14
P/S ratio
0.22

Company profile

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Name
VBI Vaccines
CEO
Jeffery R. Baxter FCMA
Headquarters Cambridge, ma
Canada
Website
Sector
Materials
Industry
Chemicals
IPO
26/04/2010
Employees 131

Ticker symbols

Exchange Symbol
NASDAQ
VBIV
Frankfurt
LO91.F
München
LO91.MU
🍪

Parqet  uses cookies. Learn more